GABA type A receptor associated protein like 2Genealiases: ATG8 · ATG8C · GATE-16 · GATE16 · GEF-2 · GEF2
Q-omics provides the consensus-scored GABARAPL2 profile across patient tissues and cancer cell-line models. GABARAPL2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GABARAPL2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, GABARAPL2 protein abundance shows 19,832 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where GABARAPL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABARAPL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABARAPL2 survival associations across molecular data types. GABARAPL2 RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABARAPL2 RNA expression–survival associations across cancer types. High GABARAPL2 expression shows unfavorable associations in STAD, BLCA, ESCA, HNSC and SCLC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GABARAPL2 RNA expression.
This table summarizes GABARAPL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GABARAPL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABARAPL2 shows lower tumor expression in KICH, LUSC, LUAD, UCEC and KIRC and higher tumor expression in LIHC. The KICH box plot shows higher GABARAPL2 RNA expression in normal versus tumor tissue (log2 FC = −0.969, t-test p < 0.001).
This table shows molecular features associated with GABARAPL2 in patient tissues and cancer cell lines. In patient samples, GABARAPL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GABARAPL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
